In this white paper, we draw lessons from industries as diverse as food products and toy manufacturing to illustrate how pharmaceutical companies can effectively access innovation outside the traditional in-house R&D model. To read more, click the PDF link below. A version of this article was also published in IN VIVO here.
ESMO 2025 Review: Bring me the horizon
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...